Revealing Invisible Prostate Cancer with VERDICT-MRI

Le résumé fourni par la source

Motivation: Prostate multi-parametric (mp)MRI misses 10-20% of PCa, presenting a need for enhanced imaging techniques. Goal(s): To determine if VERDICT-MRI, when used alongside mpMRI, can improve the detection and characterization of mpMRI-invisible lesions. Approach: We identify patients with mpMRI-invisible lesions from the Histo-MRI clinical trial (n=11). We use slice-to-slice matched whole-slide histology and MRI. We analyze differences in histological cell density, epithelial fraction and VERDICT intracellular volume fraction between mpMRI-visible and -invisible lesions. Results: Using VERDICT-MRI improves the sensitivity of detection of invisible lesions, particularly with high cell density and epithelial fraction. Impact: Integrating VERDICT-MRI into clinical imaging could enhance detection of previously invisible prostate cancer lesions, allowing for more precise stratification and more informed, personalized treatment strategies, potentially improving patient outcomes.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.